SR-17018 Reference Standard — two-tone blue/cyan research capsules
compoundLab-verified
Hero productResearch use onlycompound

SR-17018 Reference Standard

Batch SR17018-BATCH-2026-0014.73 reviews

High-purity SR-17018 reference standard for receptor pharmacology research.

Molecular information

Spec sheet

IUPAC name

2-(4-fluorophenyl)-N-[2-(1-methylethyl)-5-oxo-1,3-oxazol-4-yl]acetamide

FormulaC22H25FN2O2
CAS numberN/A (research compound)
Mol. weight368.45 g/mol
AppearanceWhite crystalline powder
SolubilitySoluble in DMSO and ethanol
Solubility detail≥10 mg/mL in DMSO; ≥5 mg/mL in ethanol with gentle warming
Storage temp.-20°C, protected from light

SMILES

CC(C)C1=NC(=O)OC1=O

Mechanism of action

SR-17018 is a small-molecule G-protein-biased μ-opioid receptor (MOR) agonist developed as a research probe for biased signal transduction at opioid receptors. It preferentially activates G-protein-mediated signaling over β-arrestin recruitment, a profile associated in preclinical models with robust analgesia alongside reduced respiratory depression and attenuated tolerance liability.

Receptor pharmacology

In vitro binding studies report Ki values of approximately 11 nM at the μ-opioid receptor (MOR), 68 nM at the κ-opioid receptor (KOR), and >10,000 nM at the δ-opioid receptor (DOR), indicating strong MOR selectivity over DOR and modest KOR affinity.

Bias factor

Functional assays quantify a signaling bias factor of roughly 80–100 relative to the reference agonist DAMGO, reflecting preferential G-protein pathway activation with diminished β-arrestin2 recruitment.

Preclinical analgesia profile

Animal models demonstrate dose-dependent antinociception with a wider therapeutic window for respiratory effects compared with morphine, and reduced antinociceptive tolerance on repeated dosing.

First description

The scaffold and biased-agonist profile were first characterized by Bohn and colleagues (2017) as part of structure–activity studies on μ-opioid biased agonists.

Research use only. Mechanism information is provided for research and educational reference only. SR-17018 is not approved for diagnostic, therapeutic, or human use.

Batch purity & potency trend

3 batches
SR17018-BATCH-2026-001SR17018-BATCH-2026-00190%93%96%100%
Purity Potency

Certificate of analysis

COA-SR17018-2026-001

Lab

Factory Reset QC Laboratory

Test date

Jan 1, 1970

Purity

99.70%

m/z (MS)

369.18

NMR confirmation

1H NMR (400 MHz, DMSO-d6): consistent with SR-17018 reference spectrum

Expiry

Jan 1, 1970

TestMethodSpecificationResultInstrumentRT / AreaStatus
HPLC PurityHPLC-UV≥ 98.0%99.7%HPLC-048.42 min · A=1,842,300 · 99.7% Pass
Mass SpectrometryLC-MSMatch to theoreticalm/z 369.18 [M+H]+LCMS-02 Pass
NMR Confirmation1H NMRConsistent with referenceConsistent with structureNMR-01 Pass

Technician

J. Patel, QC Analyst

Reviewer

Dr. M. Chen, QC Director

Batch history

Batch synthesized and quarantined

by Synthesis Team A

Jan 1, 1970

Sampling for QC release testing

by J. Patel, QC Analyst

Jan 1, 1970

Certificate of Analysis issued

by Dr. M. Chen, QC Director

Jan 1, 1970

Reviews (3)

4.7
Dr. Elena VasquezVerified

Excellent purity and consistency. The CoA documentation was thorough and the HPLC data matched our independent verification.

Jan 1, 1970

Research Lab TechVerified

SR-17018 from Factory Reset is the most consistent we've worked with. Batch-to-batch reproducibility is outstanding.

Jan 1, 1970

Pharmacology PostdocVerified

Great product. Shipping was fast and the technical data sheet was comprehensive.

Jan 1, 1970

Factory Reset logoFactory Reset

Are you 21 years of age or older?

This site contains research-grade reference standards. Access is restricted to verified adults.

By continuing you confirm you meet the legal age requirement.